178 related articles for article (PubMed ID: 37627042)
1. Editorial: 'Engineering the Tumor Immune Microenvironment' Special Issue.
Ahmad RN; Verbridge SS
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627042
[TBL] [Abstract][Full Text] [Related]
2. Editorial on Special Issue "Immunotherapy, Tumor Microenvironment and Survival Signaling".
Golubovskaya V
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008254
[TBL] [Abstract][Full Text] [Related]
3. Guest Editorial: what can be done to improve cancer immunotherapies?
Tamura H
Int J Hematol; 2023 May; 117(5):631-633. PubMed ID: 36964838
[TBL] [Abstract][Full Text] [Related]
4. Editorial: The intricate innate immune-cancer cell relationship in the context of tumor angiogenesis, immunity and microbiota: The angiogenic switch in the tumor microenvironment as a key target for immunotherapies.
Mortara L; Benest AV; Derosa L; Chouaib S; Ribatti D
Front Immunol; 2022; 13():1045074. PubMed ID: 36275734
[No Abstract] [Full Text] [Related]
5. Role for extracellular vesicles in the tumour microenvironment.
O'Loghlen A
Philos Trans R Soc Lond B Biol Sci; 2018 Jan; 373(1737):. PubMed ID: 29158316
[TBL] [Abstract][Full Text] [Related]
6. Engineering Nanoparticles to Reprogram the Tumor Immune Microenvironment for Improved Cancer Immunotherapy.
Saeed M; Gao J; Shi Y; Lammers T; Yu H
Theranostics; 2019; 9(26):7981-8000. PubMed ID: 31754376
[TBL] [Abstract][Full Text] [Related]
7. Royal Society Scientific Meeting: Extracellular vesicles in the tumour microenvironment.
Pink RC; Elmusrati AA; Lambert D; Carter DRF
Philos Trans R Soc Lond B Biol Sci; 2018 Jan; 373(1737):. PubMed ID: 29158319
[TBL] [Abstract][Full Text] [Related]
8. Erratum to: 'Hedgehog signaling: modulation of cancer properties and tumor microenvironment'.
Hanna A; Shevde LA
Mol Cancer; 2016 May; 15(1):35. PubMed ID: 27169588
[No Abstract] [Full Text] [Related]
9. Editorial: Cancer Immunotherapies: From Efficacy to Resistance Mechanisms.
Chandra J; Hansen M; Labarriere N; Marigo I; Souza-Fonseca-Guimaraes F; Vujanovic L; Koguchi Y; Jacquelot N
Front Immunol; 2022; 13():939789. PubMed ID: 35720421
[No Abstract] [Full Text] [Related]
10. Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies.
Abate-Daga D; Rosenberg SA; Morgan RA
Oncoimmunology; 2014; 3():e29194. PubMed ID: 25083334
[TBL] [Abstract][Full Text] [Related]
11. Modulation of Immune Infiltration of Ovarian Cancer Tumor Microenvironment by Specific Subpopulations of Fibroblasts.
Wang J; Cheng FHC; Tedrow J; Chang W; Zhang C; Mitra AK
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33138184
[TBL] [Abstract][Full Text] [Related]
12. New Therapeutics for HCC: Does Tumor Immune Microenvironment Matter?
Khanam A; Kottilil S
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613878
[TBL] [Abstract][Full Text] [Related]
13. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives.
Mao X; Xu J; Wang W; Liang C; Hua J; Liu J; Zhang B; Meng Q; Yu X; Shi S
Mol Cancer; 2021 Oct; 20(1):131. PubMed ID: 34635121
[TBL] [Abstract][Full Text] [Related]
14. Reprogramming the tumor microenvironment to improve the efficacy of cancer immunotherapies.
Faraj JA; Al-Athari AJH; Mohie SED; Kadhim IK; Jawad NM; Abbas WJ; Jalil AT
Med Oncol; 2022 Sep; 39(12):239. PubMed ID: 36175691
[TBL] [Abstract][Full Text] [Related]
15. Tumor immune microenvironment and nano-immunotherapeutics in colorectal cancer.
Xiong Y; Wang Y; Tiruthani K
Nanomedicine; 2019 Oct; 21():102034. PubMed ID: 31207314
[TBL] [Abstract][Full Text] [Related]
16. The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.
Gajewski TF
Semin Oncol; 2015 Aug; 42(4):663-71. PubMed ID: 26320069
[TBL] [Abstract][Full Text] [Related]
17. Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment.
Melo V; Bremer E; Martin JD
Front Cell Dev Biol; 2022; 10():908389. PubMed ID: 35712656
[TBL] [Abstract][Full Text] [Related]
18. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
Tang T; Huang X; Zhang G; Hong Z; Bai X; Liang T
Signal Transduct Target Ther; 2021 Feb; 6(1):72. PubMed ID: 33608497
[TBL] [Abstract][Full Text] [Related]
19. Cancer-derived extracellular vesicles: friend and foe of tumour immunosurveillance.
Dörsam B; Reiners KS; von Strandmann EP
Philos Trans R Soc Lond B Biol Sci; 2018 Jan; 373(1737):. PubMed ID: 29158311
[TBL] [Abstract][Full Text] [Related]
20. Editorial: Tumor microenvironment, inflammation, and resistance to immunotherapies.
Decock J; Comito G; Zaravinos A
Front Oncol; 2023; 13():1215332. PubMed ID: 37324002
[No Abstract] [Full Text] [Related]
[Next] [New Search]
